Announcements Trials
Browse Landscape

Phase

Phase 2/3 2Phase 2 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Burkitt Lymphoma 5Multiple Myeloma 4Lung Neoplasms 3Leukemia, Biphenotypic, Acute 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Vomiting 1Smoldering Multiple Myeloma 1Recurrence 1Ovarian Neoplasms 1Nausea 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Fallopian Tube Neoplasms 1Down Syndrome 1Brenner Tumor 1

Interventions

Radiotherapy 31Carboplatin 29Cisplatin 28Paclitaxel 26Gemcitabine 14Docetaxel 14Etoposide 13Bevacizumab 9Ramucirumab 7Pemetrexed 6Magnetic Resonance Spectroscopy 5Erlotinib Hydrochloride 5Cetuximab 5pembrolizumab 4cediranib 4Vinorelbine 4Specimen Handling 4Radiosurgery 4Gene Expression Profiling 4Filgrastim 4Amplified Fragment Length Polymorphism Analysis 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Surgical Procedures, Operative 3Radiotherapy, Conformal 3Psychiatric Rehabilitation 3Polymerase Chain Reaction 3Neoadjuvant Therapy 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Lung Neoplasms × dexamethasone acetate × Clear all
NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Active not recruiting
82 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06616584 2026-05-05

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2/3 Recruiting
378 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04267913 2020-11-20

Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 2 Withdrawn
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡